Payer Perspective for Biotech Innovations in Autoimmune Diseases in the US

CHALLENGE

A prominent biotech company based in Europe sought to gain critical insights into the payer perspective of a novel product they were developing for an autoimmune disease. The objective was to understand the reimbursement landscape, required criteria, and overall market access for the disease in the United States. The client's concerns revolved around questions such as: the criteria for payer acceptance, the current landscape of the disease, and the reimbursement trends for new drugs.

OUR APPROACH

BTHT initiated a comprehensive strategic analysis to address the project's scope. This involved a meticulous examination of the payer landscape within the U.S., focusing on reimbursement, market access, and pricing strategies for the disease in question. Our team engaged with experts possessing extensive knowledge of the U.S. payer system and the specific disease. The profiles included: - Former Lead Director of Strategic Planning at a leading private insurance company - Former Senior Director of Strategic Contracting at a leading private insurance company - Former Senior VP/Chief Compliance Officer at various insurance companies/organizations. - Former COO and Director at different public and private insurance companies.

The team planned meticulously targeted interviews, and ensured that the the process went smoothly during and after the consultation.

OUTCOME

Our thorough and strategic approach delivered valuable insights for the client. Through focused consultations with industry experts, we provided the client with a deep understanding of the U.S. payer landscape. This enabled them to make informed decisions, develop effective market access strategies, and navigate the complexities of reimbursement and pricing for their product in the United States.